Tactile Medical reports 23% revenue growth and narrows net loss in Q1 2026

Tactile Medical posted a 23% increase in Q1 2026 revenue to $75.3 million, driven by strong sales in lymphedema and airway clearance products. The company improved its gross margin to 76.5% and reduced its net loss to $1.8 million from $3.0 million a year earlier. Adjusted EBITDA turned positive at $3.7 million, reflecting operational leverage and strategic execution. Tactile Medical also updated its 2026 revenue outlook, expecting growth of 9% to 12%, supported by product innovation and expanded market access.